Prostate Cancer Prognostic Test Maker Aureon Biosciences Closes Shop
October 12, 2011
Prostate Cancer Prognostic Test Maker Aureon Biosciences Closes Shop
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Prostate Cancer MDx Competition Heating Up; New Data from Genomic Health, Myriad
May 15, 2013 / Pharmacogenomics Reporter - With 8 Percent Revenue Bump in Q1, Genomic Health Focus on Expanding Oncotype DX Franchise
May 8, 2013 / Pharmacogenomics Reporter - Wall Street Closely Tracking Validation Data on Genomic Health's Oncotype DX Prostate Cancer Test
April 3, 2013 / Pharmacogenomics Reporter - After 14 Percent Revenue Bump in 2012, Genomic Health Focusing on Market Growth, Prostate Dx Launch
February 13, 2013 / Pharmacogenomics Reporter - Genomic Health Attributes Q3 Revenue Growth to Strong International Test Adoption
November 14, 2012 / Pharmacogenomics Reporter